
US FDA halts Sun Pharma’s trial on dermatological drugs; stock down
The federal agency has put on hold the trial of 12 mg of Deuruxolitinib clinical trial owing to a potential pulmonary embolism.
The federal agency has put on hold the trial of 12 mg of Deuruxolitinib clinical trial owing to a potential pulmonary embolism.
Cyrus Soli Poonawalla’s Serum Institute of India made the most of the country’s demand for vaccines.
The Sensex and Nifty are poised to start the week on a negative note, tracking weak cues from global peers and bearish trading on the SGX Nifty futures.
Sun Pharma incurred an exceptional loss of ₹3,936 crore on account of settlements, provisions related to Taro Pharmaceuticals, Ranbaxy.
Shares of Sun Pharmaceutical Industries climbed nearly 1% in opening trade, while Zenotech Laboratories was locked in an upper circuit of 5% on the BSE.
The BSE Sensex and the NSE Nifty are set to start the week on a bearish note, following soft cues from Asian peers and negative trade at SGX Nifty.
This was the third-best performance by the domestic bourses on a Budget day in the last ten years, with Sensex surging 1.46% to 58,862 points.
Dalal Street headed for a negative start on Wednesday, following weak cues from Asian peers as market participants remained concerned about the Omicron variant of Covid-19.
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.